Abstract: Objective To investigate the efficacy and tolerability of albuminbound paclitaxel（ABX） based chemotherapy in recurrent ovarian cancer and primary peritoneal cancer. Methods Patients who treated with ABX based chemotherapy between January 2010 and November 2012 at Fudan University Shanghai Cancer Center were analyzed retrospectively. Response was evaluated per GCIG CA125 or RECIST criteria. The frequence of dose reduction， treatment delay and interruption were assessed for treatment tolerability. Results 15.6％（5／32）and 84.4％（27／32） of the patients were platinumsensitive and primary／sencondary platinum resistant／refractory，respectively. At baseline， mean serum CA125 value was （477.5±654.9）U／ml and 26（81.3％） had elevation of CA125. The overall response rate was 28.0％（9／32）， with CA125 complete responses in 5 patients. Response rate was 60.0％（3／5） in platinumsensitive and 22.2％（6／27） in platinum resistant／refractory recurrences with no statistical difference（P＞0.05）. Six courses in 5 patients were delayed over one week and neither dose reductions or treatment interruptions nor hypersensitivity to ABX were noted. Conclusion Nab-paclitaxel based regimens are effective in platinum sensitive or platinum resistant recurrences and generally well tolerated in heavily pretreated patients with epithelial ovarian cancer and primary peritoneal cancer.